-
Industry leader Ed Shifflett, PhD joins MOMENTUS as Chief Growth Officer & Managing Partner
Written by
MOMENTUS BioPharma Consulting Group announced today that Ed Shifflett, PhD has joined the company as Chief Growth Officer and Managing Partner. John “Zeke” Czekanski, CEO, shared “The growth and trajectory of the company support Ed joining us as Chief Growth Officer and a full partner. Clients have responded extremely well to our forward-thinking strategies driven by innovative and integrated solutions across the therapeutic lifecycle. Ed’s experience building and scaling successful, client-focused businesses positions us well…
-
The MOMENTUS Approach to Readiness: Navigating the New Era of BioPharma Transformation
Written by
Biopharma leaders regularly tell us that the pace and magnitude of transformation are raising the bar for every decision. Data, speed, and advanced analytics are redefining how therapies are developed, accessed, and delivered, placing greater emphasis on value and, ultimately, better patient outcomes. Forward-thinking, cost-effective, nimble strategies that accelerate the approval and adoption of life-changing therapies are essential for successful partnerships with today’s biopharma clients. The MOMENTUS Readiness Platform was designed to meet this demand.…
-
MFN Monitor: Europe’s Drug Launch Model Is Becoming a U.S. Pricing Risk
Written by
Traditional Global Launch Strategies Are Now Under Pressure For decades, the commercial path for innovative therapeutics followed a relatively predictable pathway. Secure FDA-approval, establish strategic pricing and a robust commercial footprint in US, and expand into Europe shortly thereafter. That framework has now come under attack due to the uncertainty related to the pricing policy debate between biopharma and the current US administration. The growing political and regulatory scrutiny surrounding Most Favored Nation (MFN) drug…
-
Most Favored Nation (MFN) Is Altering Biopharma Drug Pricing Forever
Written by
Key Takeaways Target Audiences Innovative Biopharma Executives (US)Executives with assets in early stages of development or nearing US FDA approval, as well as those seeking ex-US launch partners. Big Pharma Executives in ex-US AffiliatesExecutives who are part of the OECD19 and simply trying to understand the pressures being faced by their global and US colleagues, and anticipate global launch governance pressures from the center. Call to Action Discover the strategies helping pharma and biotech leaders…
-
J.P. Morgan Healthcare Conference, the “Superbowl of Healthcare” – 2026 Watchlist
Written by
In December 2025, as we prepare for JP Morgan Healthcare on Jan 12-15, 2026, the U S Congress will be refining federal government funding of US Healthcare as influenced by the One Big Beautiful Bill Act (OBBBA). Spending on Medicare Part D drugs and overall Medicaid programs are once again in the cross hairs, and recent drug pricing and reimbursement reforms are likely to intensify in 2026. Prescription Drug Spending and Funding Trends According to…
-
Industry Leaders Scott Roberts and John “Zeke” Czekanski Launch MOMENTUS Biopharma Consulting
Written by
LANTANA, Fla., Nov. 5, 2025 /PRNewswire/ — Industry leaders Scott Roberts and John “Zeke” Czekanski announced today they have partnered to form MOMENTUS Biopharma Consulting, LLC (“MOMENTUS” or “the Company”), a purpose-built strategic consulting group. Headquartered in Lantana, FL with an additional location in Boston, MA, MOMENTUS offers integrated strategic solutions across the therapeutic life cycle, sharpening the focus on value and driving better outcomes for patients. The MOMENTUS platform will strive to harness new technologies, leverage Artificial Intelligence (AI), while offering human-input…
